Study: Lactobacillus Reuteri Against Colic

A clinical study of the effect of Lactobacillus reuteri on colic, which was recently in the scientific journal Pediatrics, has received much attention in the media. The latest was on Swedish Radio P1, science radio and the American TV channel ABC.

The study was a comparison between Swedish BioGaia probiotic oil drops containing Lactobacillus reuteri and the medicine that is normally used against colic. The study showed that 95% of the infants who received the BioGaia Probiotic drops responded to the treatment whilst only 7% of infants responded to the medicine. The BioGaia infants screamed 2 hours and 16 minutes less per 24-hour period. See link to the study: http://pediatrics.aapublications.org/current.shtml

Lactobacillus reuteri is a specially developed probiotic lactobacillus, the use of which is patented by BioGaia and it is not comparable with the lactobacilli that are used to give taste and texture in fermented milks or yoghurts. According to the WHO definition, probiotics are only those lactobacilli that have been tested in clinical studies with positive effect.

BioGaia has performed 37 clinical studies on a total of 3045 subjects with Lactobacillus reuteri and have shown its positive effects on human health.

BioGaia Probiotic drops are sold in eleven countries and launch is planned in a further eleven countries during 2007. BioGaia expect that the drops will be launched in Sweden during 2007. The product is already used in a number of Swedish hospitals.

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the small cap list of the Stockholm Stock Exchange.

www.biogaia.com

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health effects. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (ReuteriÒ), which has probiotic or health-enhancing effects. The Parent Company BioGaia AB's class B share is quoted on the O list of the Stockholm Stock Exchange.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish